Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its nuclear import, as well as its ability to bind to DNA. Apalutamide has a similar mechanism of action to Xtandi (enzalutamide; Pfizer/Astellas). However, in preclinical development, apalutamide exhibited reduced binding to plasma proteins, which resulted in increased efficacy at lower exposure rates than those required for Xtandi. Brain-levels (the concentration of the drug in brain tissue) were lower for apalutamide than for Xtandi, which could indicate a lower seizure-induction risk with apalutamide.
Apalutamide is poised to become the next AR inhibitor to reach the market following the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in non-metastatic castration-resistant prostate cancer (nmCRPC) patients. The submission to the FDA was based on the Phase III SPARTAN trial, which met its primary endpoint of metastasis-free survival (MFS). Approval in this population would expand Johnson & Johnson’s prostate cancer treatment portfolio and pair an AR inhibitor with its blockbuster 17 alpha-hydroxylase (CYP17) inhibitor Zytiga (abiraterone acetate). However, if approved, apalutamide may face direct competition from the established AR inhibitor Xtandi, which also improved MFS in nmCRPC patients in the Phase III PROSPER study.
TABLE OF CONTENTS
4 Product Profiles
4 apalutamide : Prostate cancer
LIST OF FIGURES
11 Figure 1: Apalutamide for prostate cancer – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of apalutamide for prostate cancer
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of apalutamide for prostate cancer
15 Figure 4: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Apalutamide drug profile
6 Table 2: Apalutamide Phase III data in prostate cancer
9 Table 3: Apalutamide Phase I/II data in prostate cancer
16 Table 4: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.